GMP Certified / Moxifloxacin Hydrochloride and Sodium Chloride Injection 400mg/250ml

• Customization: Available
• Quality Standard: Bp, USP
• Ctd Dossier: Ready
• Model NO.: injection
• Documentation: Copp, COA
• Factory Certification: GMP
• Transport Package: Carton
• Specification: 400mg/250ml
• Trademark: Sinolead
• Origin: China
• Production Capacity: 100, 000, 000 Per Year

Product Description

 

Generic Name	Moxifloxacin Hydrochloride and Sodium Chloride Injection 400mg/250ml
Strength	400mg/250ml
Packing	1 bottle / box
Origin	China

Value-added services:
 Packaging design by our team
 Registration service by our team
 Registration dossier available by our team
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Product name:
Moxifloxacin Hydrochloride and Sodium Chloride Injection 400mg/250ml

Character:
 This product is a yellow clarified liquid.

Indications:
Adults (≥18 years) with upper and lower respiratory tract infections, such as acute sinusitis, acute episodes of chronic bronchitis, community-acquired pneumonia; And skin and soft tissue infections.
Complex abdominal infections include mixed bacterial infections, such as abscesses.

Matters needing attention
Moxifloxacin can prolong the QT interval of the electrocardiogram in some patients. The drug should be avoided in patients with prolonged QT interval, patients with uncorrected hypokalemia, and patients receiving Class Ia (e.g., quinidine, procayamine) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications.
Moxifloxacin and drugs that may prolong the QT interval: cisapride, erythromycin, antipsychotics, and tricyclic antidepressants, may have an additive effect when taken in combination. Therefore, these drugs should be used with caution.
Moxifloxacin should be used with caution in the presence of arrhythmogenic conditions, such as severe bradycardia or acute myocardial ischemia.
Because female patients tend to have a longer QTc interval than men, they may be more sensitive to drugs that trigger a prolonged QTc interval. Older patients are also more likely to suffer from drug-induced QT interval prolongation.
The degree of QT interval prolongation increases with the increase of drug concentration. So you should not exceed the recommended dose. However, no correlation between moxifloxacin serum concentration and QT interval prolongation was observed in patients with pneumonia. Prolonged QT interval may increase the risk of ventricular arrhythmias including tip torsion ventricular tachycardia. In a clinical study of more than 9,000 patients treated with moxifloxacin, there was no cardiovascular morbidity or mortality associated with prolonged QT interval, but certain underlying conditions can increase the risk of ventricular arrhythmias.
Female patients and older patients are more sensitive to drugs that trigger a prolonged QTc interval.
Moxifloxacin has been reported to cause explosive hepatitis, which may lead to liver failure (including death). If symptoms related to liver failure occur, patients should be advised to contact their doctor immediately before continuing treatment.
Bullous skin reactions caused by moxifloxacin have been reported, such as Stevens-Johnson syndrome or toxic epidermal necrolysis. If a skin and/or mucosal reaction occurs, the patient should be advised to contact a doctor immediately before continuing treatment.
Quinolone use can induce seizures, and moxifloxacin should be used with caution in patients with known or suspected central nervous system disorders that can cause seizures or reduce the seizure range.
Tendinitis and tendon rupture are possible in treatment with quinolones including moxifloxacin, especially in older patients and those using hormone therapy. Once pain or inflammation occurs, the patient needs to stop taking the medication and rest the affected limb.
Pseudomembranous enteritis has been reported with the use of broad-spectrum antibiotics, including moxifloxacin, so it is important to consider this diagnosis when patients develop severe diarrhea during moxifloxacin therapy. In this case, adequate treatment should be taken immediately. In patients with severe diarrhea, drugs that inhibit gastrointestinal motility should be contraindicated.
Moxifloxacin should be used with caution in patients with myasthenia gravis because it can worsen symptoms.
Quinolones have been shown to cause photosensitization in patients. However, no photosensitization of moxifloxacin was observed in specially designed preclinical and clinical studies. In addition, there is no clinical evidence that moxifloxacin causes photosensitization since its introduction. Nevertheless, patients should be advised to avoid excessive exposure to UV light and sunlight.
In some cases, if allergic reactions and allergies have occurred after the first dose, the doctor should be informed immediately.
Life-threatening shock from anaphylaxis can occur in rare cases after the first dose. In these cases moxifloxacin should be discontinued and treated (e.g., for shock).
For patients with complex pelvic infections (such as tubo-ovarian or pelvic abscesses), intravenous administration should be considered, and oral moxifloxacin 400mg is not recommended.
For those patients whose sodium intake is a clinical concern (congestive heart failure, renal failure, nephrotic syndrome, etc.), additional sodium load should be considered.
Fluoroquinolones, including moxifloxacin, may impair a patient's ability to drive or operate machinery due to central nervous system (CNS) reactions.
Insert the needle of the infusion set vertically into the center of the inner ring of the rubber plug. Do not exert too much force to avoid damage to the rubber plug.

Storage:
Dark, sealed, stored above 15ºC. Store in original packaging. Do not refrigerate or freeze. Precipitation occurs when refrigerated and can be redissolved at room temperature. Therefore, it is recommended not to store moxifloxacin hydrochloride sodium chloride injection in the refrigerator. Keep medicines out of reach of children.